The MHRA has issued a drug safety alert regarding the link between PPI use and the risk of hypomagnesaemia but did not provide guidance on how regularly patients should be monitored. In this small cohort the authors identified a subgroup of patients that were also taking diuretics that seemed to be at higher risk of developing low magnesium levels and recommend that more frequent monitoring (eg annual) alongside regular renal function monitoring should be considered in this group but question whether annual monitoring is necessary for all patients.